The TREK-1 potassium channel is a potential pharmacological target for vasorelaxation in pulmonary hypertension.
Réka CsákiChandran NagarajJános AlmássyMohammad Ali KhozeimehDusan JeremicHorst OlschewskiAlice DobolyiKonrad HoetzeneckerAndrea OlschewskiPéter EnyediMiklós LengyelPublished in: British journal of pharmacology (2024)
homeostasis of hPASMC, and therefore, essential for maintenance of a low resting pulmonary vascular tone. Thus TREK-1 may represent a new therapeutic target for PAH.